Dublin-headquartered Californian firm Theravance Biopharma (Nasdaq: TBPH) has announced positive new data from multiple studies of Vibativ (telavancin) at IDWeek 2018.
The firm says it expects the new data will help with “optimizing use in patients currently being treated with Vibativ,” as well as “highlighting subsets of patients that may be most appropriate for treatment.”
Vibativ is a once-daily, injectable lipoglycopeptide antibiotic, approved in the USA for various infectious diseases, including for the treatment of certain adult patients with hospital-acquired infections.
Findings from one study reported a positive clinical response following Vibativ treatment in 77.1% of certain registry patients diagnosed with monomicrobial infections.
Results from a second study demonstrated that renal function was unchanged in 68.7% of patients who received treatment with Vibativ for more than 21 days and had creatinine clearance (CrCl) measured at baseline and end of treatment.
Lead author Micah Jacobs said: “These data from TOUR highlight that Vibativ should be considered one of those alternative treatment options in this era of rising vancomycin MICs in order to ensure patients are getting effective therapy.”
